LKB1 (Thr363) Polyclonal Antibody
Catalogue Number: BS-1532R-BSS
BS-1532R Image
BS-1532R Image
BS-1532R Image
BS-1532R Image
Formalin-fixed and paraffin embedded human brain labeled with Anti-phospho-LKB1 (Thr363)Polyclonal Antibody, Unconjugated (bs-1532R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
BS-1532R Image
Formalin-fixed and paraffin embedded human esophagus carcinoma labeled with Anti-phospho-LKB1 (Thr363)Polyclonal Antibody, Unconjugated (bs-1532R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
BS-1532R Image
HepG2 cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20°C, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with phospho-LKB1 (Thr363) Antibody(bs-1532R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).
| Manufacturer: | Bioss Inc |
| Shelf Life: | 12 months |
| Type: | Polyclonal Primary Antibody - Unconjugated |
| Alias: | PJS; LKB1; hLKB1; Serine/threonine-protein kinase STK11; Liver kinase B1; Renal carcinoma antigen NY-REN-19; STK11 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ul |
| Host name: | Rabbit |
| Clone: | |
| Isotype: | IgG |
| Immunogen: | KLH conjugated synthetic phosphopeptide derived from human LKB1 around the phosphorylation site of Thr363 [IY(p-T)QD] |
| Application: | ELISA, ICC, IF, IHC-P, IHC-Fr |
Description
Description: Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signaling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to the mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways. In vein endothelial cells, inhibits PI3K/Akt signaling activity and thus induces apoptosis in response to the oxidant peroxynitrite (in vitro). Isoform 2: Has a role in spermiogenesis.
Additional Text
Gene Name
STK11
Uniprot ID
Q15831
Gene ID
6794
Purification
Protein A purified
Concentration
1 ug/ul
Antibody Clonality
Polyclonal
Modification
Phosphorylated, Thr363
Storage Note
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
bs-1532R Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations